Cargando…

Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines

Cisplatin is widely employed as a first-line chemotherapeutic agent for many solid tumors, including malignant pleural mesothelioma (MPM). However, its clinical use is limited by heavy side effects and acquired resistance, the latter being mainly related to enhanced DNA repair. Many clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gabano, Elisabetta, Pinton, Giulia, Balzano, Cecilia, Boumya, Sara, Osella, Domenico, Moro, Laura, Ravera, Mauro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402032/ https://www.ncbi.nlm.nih.gov/pubmed/34443328 http://dx.doi.org/10.3390/molecules26164740

Ejemplares similares

The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH(3)COO)Cl(2)(NH(3))(2)(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake
por: Gabano, Elisabetta, et al.
Publicado: (2022)

Antiproliferative Activity of Pt(IV) Conjugates Containing the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Ketoprofen and Naproxen †
por: Ravera, Mauro, et al.
Publicado: (2019)

Can the Self-Assembling of Dicarboxylate Pt(IV) Prodrugs Influence Their Cell Uptake?
por: Ravera, Mauro, et al.
Publicado: (2021)

Polyanionic Biopolymers for the Delivery of Pt(II) Cationic Antiproliferative Complexes
por: Ravera, Mauro, et al.
Publicado: (2016)

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
por: Pinton, Giulia, et al.
Publicado: (2013)

Expression and therapeutic significance of estrogen receptor β in malignant pleural mesothelioma
por: Pinton, Giulia, et al.
Publicado: (2017)

Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
por: Pinton, Giulia, et al.
Publicado: (2014)

Epigenetic Insights on PARP-1 Activity in Cancer Therapy
por: Pinton, Giulia, et al.
Publicado: (2022)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
por: Srinivasan, Gayathri, et al.
Publicado: (2017)

Image-Guided Nanodelivery of Pt(IV) Prodrugs to GRP-Receptor Positive Tumors
por: Silva, Francisco, et al.
Publicado: (2023)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment
por: Boumya, Sara, et al.
Publicado: (2023)

Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma
por: Pinton, Giulia, et al.
Publicado: (2012)

Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia
por: Zonca, Sara, et al.
Publicado: (2017)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells
por: Pinton, Giulia, et al.
Publicado: (2016)

Intracellular lactate-mediated induction of estrogen receptor beta (ERβ) in biphasic malignant pleural mesothelioma cells
por: Manente, Arcangela G., et al.
Publicado: (2015)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022)

CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition
por: Pinton, Giulia, et al.
Publicado: (2021)

Perfluorophenyl Derivatives as Unsymmetrical Linkers for Solid Phase Conjugation
por: Alapour, Saba, et al.
Publicado: (2018)

Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition
por: Pinton, Giulia, et al.
Publicado: (2022)

Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009)

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma
por: Yang, Haitang, et al.
Publicado: (2023)

Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma
por: Moro, Jacopo, et al.
Publicado: (2022)

Current Developments in Pt(IV) Prodrugs Conjugated with Bioactive Ligands
por: Li, Xuejiao, et al.
Publicado: (2018)

Symmetrical and unsymmetrical α,ω-nucleobase amide-conjugated systems
por: Boncel, Sławomir, et al.
Publicado: (2010)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023)

Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers
por: Sorino, Claudio, et al.
Publicado: (2023)

Estrogen Receptor β Exerts Tumor Repressive Functions in Human Malignant Pleural Mesothelioma via EGFR Inactivation and Affects Response to Gefitinib
por: Pinton, Giulia, et al.
Publicado: (2010)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect of Pemetrexed and Cisplatin in Pleural Mesothelioma
por: Gesmundo, Iacopo, et al.
Publicado: (2022)

Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)

Pleural mesothelioma – case report
por: Klawiter, Anna, et al.
Publicado: (2010)

Heterogeneity in Malignant Pleural Mesothelioma
por: Oehl, Kathrin, et al.
Publicado: (2018)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Malignant pleural mesothelioma: an update
por: Hajj, Glaucia N. M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lfo7tvtpntmog1lfgfmb9fmm8o